OptiNose Selects BioClinica Trident IWR, Optimizer And Imaging Core Lab Solutions

Drug Delivery Company Selects BioClinica for Roster of Clinical Trials

BioClinica, Inc., a global provider of clinical trial management solutions, recently announced that OptiNose, Inc. selected BioClinica Trident IWR, Optimizer clinical supplies forecasting, and Imaging Core Lab services for use in a series of clinical trials including several pivotal Phase III studies.

"OptiNose's goal was to employ the best available technology to help us develop the highest quality products in the most efficient manner," said Colette Kosik-Gonzalez, Senior Director, Clinical Development, OptiNose, Inc. "After a thorough competitive assessment of the leading solutions, we selected BioClinica for high-quality medical image management services and cutting-edge IVR technology to provide us with maximum efficiencies throughout our programs."

OptiNose's analysis found BioClinica Optimizer and Trident IWR products to be extremely user-friendly, with the added benefit of significantly reducing study build time. OptiNose also determined that the combination of Trident and Optimizer would ease trial management and help control costs by continually assessing clinical supply requirements throughout the trial.

"Award-winning technology and a talented services group are some of the reasons why innovative companies like OptiNose choose BioClinica's advanced imaging and IWR solutions," said Mark Weinstein, CEO of BioClinica. "BioClinica's approach to supporting clinical trials is based on the understanding that trial managers want better alternatives and fewer complications to support their clinical projects. With increasing frequency, clients realize the benefits of BioClinica's services suite and select multiple products to meet their needs. OptiNose is one such example of this trend, and we are pleased to help them manage their clinical trials with greater efficiency and accuracy."

About OptiNose Inc.
OptiNose is a drug delivery company with breakthrough bi-directional nasal technology set to transform the static nasal drug delivery market. Founded in 2000, OptiNose's devices are designed to deliver intranasal drugs to target regions of the nasal cavity, including the sinuses and the olfactory region while preventing lung deposition. The company offers both single and multi-use intranasal delivery devices for liquid and powder formulations. The technology has been successfully tested in a number of clinical trials demonstrating both clinical efficacy and safety. Investors in OptiNose include Avista Capital Partners in New York, WFD Ventures LLC located in New York and Entrepreneurs Fund LP based in Jersey, Channel Islands. For more information, visit www.OptiNose.com.

About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information visit www.bioclinica.com.

SOURCE: BioClinica, Inc.